M&A Deal Summary |
|
|---|---|
| Date | 2016-02-05 |
| Target | POZEN |
| Sector | Life Science |
| Buyer(s) | Aralez Pharmaceuticals |
| Deal Type | Merger |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 2015 |
| Sector | Life Science |
| Employees | 164 |
| Revenue | 106M USD (2017) |
Aralez Pharmaceuticals is a global specialty pharmaceutical company focused on delivering meaningful products to improve patients' lives while focusing on creating shareholder value by acquiring, developing, and commercializing products primarily in cardiovascular, pain, and other specialty areas. Aralez Pharmaceuticals was founded in 2015 and is based in Mississauga, Canada.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 3 |
| Sector (Life Science) | 2 of 2 |
| Type (Merger) | 2 of 2 |
| State (North Carolina) | 1 of 1 |
| Country (United States) | 1 of 1 |
| Year (2016) | 2 of 3 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2016-02-05 |
Aralez Pharmaceuticals - Commercial Products & Infrastructure Pharmaceutical Business
Milton, Ontario, Canada Aralez Pharmaceuticals, Inc. - Commercial Products & Infrastructure Pharmaceutical Business is a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2016-10-04 |
AstraZeneca - Toprol-XL
London, United Kingdom AstraZeneca Plc - Toprol-XL is a provider of treatment of high blood pressure. By lowering blood pressure, Toprol-XL may lower the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. Toprol-XL is also indicated for the long-term treatment of angina pectoris, to reduce angina attacks and to improve exercise tolerance and for the treatment of stable, symptomatic (NYHA Class II or III) heart failure of ischemic, hypertensive, or cardiomyopathic origin. It was studied in patients already receiving ACE inhibitors, diuretics, and, in the majority of cases, digitalis. In this population, Toprol-XL decreased the rate of mortality plus hospitalization, largely through a reduction in cardiovascular mortality and hospitalizations for heart failure. |
Buy | $175M |
